SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Employees

2,426

Sector

Pharmaceuticals

Calendar

12-17 - Extraordinary Shareholders Meeting

More about the company

Quotes

Date	Price	Change	Volume
25-12-12	71.66 ¥	+0.87%	9,604,890
25-12-11	71.04 ¥	-0.69%	5,184,971
25-12-10	71.53 ¥	-2.35%	6,046,943
25-12-09	73.25 ¥	+0.22%	6,336,004
25-12-08	73.09 ¥	+0.16%	6,114,618

End-of-day quote Shenzhen S.E., December 11, 2025

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2025-12-12			5-day change	1st Jan Change
71.66 ^CNY	+0.87%		-1.80%	+43.77%

12-08	Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue	MT
10-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

Capitalization	17.66B 2.5B 2.13B 1.99B 1.87B 3.45B 227B 3.77B 23.25B 9.02B 107B 9.39B 9.19B 390B	P/E ratio 2023	94.5x	P/E ratio 2024	36.2x
Enterprise value	17.5B 2.48B 2.11B 1.97B 1.86B 3.42B 225B 3.74B 23.05B 8.94B 106B 9.31B 9.11B 386B	EV / Sales 2023	15.2x	EV / Sales 2024	6.21x
Free-Float	68.04%	Yield 2023	2.03%	Yield 2024	2.15%

12-08	Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue	MT
10-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
10-09	Shenyang Xingqi Pharmaceutical Gets China Clinical Trial Nod for Macular Edema Injection	MT
09-16	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on 24 September 2025	CI
08-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Cash Dividend for the Year 2025	CI
08-27	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
06-17	Xingqi Pharmaceutical Begins Phase Three Trial for Anesthetic Gel	MT
05-30	Xingqi Pharmaceutical Says No Adverse Effects Seen in Phase 1 Eye Drops Trial	MT
05-26	Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 850 million in funding	CI
05-15	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Final Cash Dividend Plan on A Shares for 2024, Payable on 22 May 2025	CI
04-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
04-22	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year 2024	CI
04-20	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

1 day	+0.87%
1 week	-1.80%
Current month	-0.32%
1 month	-3.54%
3 months	-0.91%
6 months	+34.98%
Current year	+43.77%

Shenyang Xingqi Pharmaceutical Co.,Ltd. Stock

Equities

300573

CNE100002DV1

Pharmaceuticals

Valuation: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Chart: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Latest news: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Press Releases: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	70.51	74.55
1 month	68	75.76
Current year	46.45	85.65
1 year	46.45	85.65
3 years	41.36	153.11
5 years	28.36	153.11
10 years	2.26	153.11

Manager	Title	Age	Since
E Gao CEO	Chief Executive Officer	51	2022-07-17
Ya Nan Cheng DFI	Director of Finance/CFO	51	2011-11-11
Chun Hua Li ADM	Chief Administrative Officer	48	2022-02-15

Director	Title	Age	Since
Ji Dong Liu CHM	Chairman	68	2000-07-04
E Gao BRD	Director/Board Member	51	2011-11-11
Shao Yao Zhang BRD	Director/Board Member	55	2015-01-14

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+0.87%	-1.80%	+17.83%	+39.46%	2.5B
MERCK KGAA	-0.38%	-1.86%	-17.29%	-34.93%	60.15B
KYOWA KIRIN CO., LTD.	+1.03%	+0.41%	+3.95%	-17.09%	8.58B
HALOZYME THERAPEUTICS, INC.	+0.50%	-1.77%	+30.06%	+7.17%	7.32B
SK BIOPHARMACEUTICALS CO., LTD.	-1.84%	-0.60%	+26.86%	+82.47%	7.06B
YUHAN CORPORATION	+0.86%	-0.26%	+0.09%	+122.78%	5.91B
INDIVIOR PLC	-0.64%	+1.25%	+209.22%	+69.25%	4.44B
BETTA PHARMACEUTICALS CO., LTD.	-0.87%	+0.06%	-12.91%	-6.25%	2.84B
SUPERNUS PHARMACEUTICALS, INC.	+1.40%	+3.24%	+30.42%	+32.66%	2.7B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+0.10%	-0.77%	-19.23%	+1.99%	1.95B
Average	+0.26%	-0.16%	+26.90%	+29.75%	10.35B
Weighted average by Cap.	-0.10%	-1.18%	+3.73%	-3.93%

	2023	2024
Net sales	1.47B 208M 177M 166M 156M 287M 18.84B 313M 1.93B 749M 8.88B 781M 764M 32.4B	1.94B 275M 235M 219M 206M 380M 24.95B 415M 2.56B 992M 11.76B 1.03B 1.01B 42.91B
Net income	240M 34.02M 28.98M 27.07M 25.47M 46.9M 3.08B 51.24M 316M 123M 1.45B 128M 125M 5.3B	338M 47.92M 40.82M 38.13M 35.88M 66.05M 4.34B 72.16M 445M 173M 2.05B 180M 176M 7.46B
Net Debt	-401M -56.88M -48.45M -45.26M -42.58M -78.4M -5.15B -85.65M -528M -205M -2.43B -213M -209M -8.86B	-155M -21.94M -18.69M -17.46M -16.43M -30.25M -1.99B -33.04M -204M -79.06M -937M -82.34M -80.6M -3.42B